#### AusE, PrhA-V150L/A232S/(M241V) a



#### AusE, PrhA-V150L/A232S/(M241V)  $\mathbf b$





#### $\mathbf d$ AusE, PrhA-V150L/A232S/M241V



# PrhA-V150L/A232S/(M241V) e  $C<sub>K</sub>$  $2) + O_2$  $3) - CO$  $\overline{12}$  $\overset{\mathsf{OH}_2}{\mathsf{e}}$ <sup>II</sup><sup>...</sup> Asp  $R = -CH<sub>2</sub>CH<sub>2</sub>COO$  $f$ PrhA-V150L/A232S/M241V  $arcc$  $2) + O_2$  $3) - CO<sub>2</sub>$  $\overline{A}$ 15  $R = -CH<sub>2</sub>CH<sub>2</sub>COO$ PrhA-V150L/A232S/M241V g  $\alpha$ KC  $2) + O<sub>2</sub>$  $- CO<sub>2</sub>$ <br>+ 13 His CH<sub>2</sub>CH<sub>2</sub>COO  $1) + \alpha$ KG  $2) + O<sub>2</sub>$ <br>3) - CO<sub>2</sub>

**Supplementary Figure 1. Proposed mechanism for AusE, PrhA, and these mutants.** (**a**) **5** is desaturated to form **6** through hydrogen atom abstraction at C-2 followed by the second hydrogen atom abstraction at C-1. (**b**) Conversion of **6** into **7** initiates with hydrogen atom abstraction at C-5. In path A, radical rebound from the top face results in the C-5 hydroxylation followed by rearrangement involving dehydration. This mechanism requires a base for the deprotonation of H-9. In path B, radical rearrangement results in cyclopropylcarbinyl radical formation, followed by ring opening to form the spirocyclic ring. The second hydrogen abstraction at C-9 forms the B-ring double bond. (**c**) Proposed mechanism for PrhA and AusE-L150V/S232A converting **5**

into **11** through hydrogen atom abstraction at C-5 and C-6. (**d**) AusE and PrhA-V150L/A232S/M241V convert **3** into **4** or **8** through initial hydrogen atom abstraction at C-3 or C-5, respectively. (**e**) PrhA-V150L/A232S/(M241V) converts **7** into **13** through initial hydrogen atom abstraction at C-13. (**f**) PrhA-V150L/A232S/M241V converts **14** into **15** through initial hydrogen atom abstraction at C-1. (**g**) PrhA-V150L/A232S/M241V converts **13** into **16** through initial hydrogen atom abstraction at C-13.



**Supplementary Figure 2. Metal dependency of EDTA-treated AusE activity.** HPLC profiles of the EDTA-treated AusE assays with **3**, αKG, and ascorbic acid: (**i**) without metal; (**ii**) with 10 mM FeSO4; (**iii**) with 10 mM MnCl2. (**iv**) HPLC profiles of the no-EDTA-treated assay with **3**, αKG, and ascorbic acid without metal. Chromatograms were monitored at 223 nm.



**Supplementary Figure 3. Residues involved in inter-dimer interactions in AusE-Mn/αKG crystal.** Amino acid residues located on the surface between chain B and chain D are shown as stick models. Hydrogen bonds were indicated as black dotted line. The positions of the N and C termini are indicated.



**Supplementary Figure 4. Comparison of the overall structures and the active sites of AusE and PrhA. (a-b)** The overall structures of **(a)** AusE and (**b**) PrhA with the positions of the N and C termini indicated. One of the monomeric subunits is colored in yellow (**a**), cyan (**b**), and the other is colored in gray. The co-substrate α-ketogluarate (αKG, white) and the substrate **5** (white) are shown as stick models.



**Supplementary Figure 5. The dimer interface of AusE and PrhA. (a)** The dimer interface of AusE and **(b)** PrhA with residues in contact shown in sticks. The hydrogen bonds are represented as yellow dotted line. The positions of the N and C termini are indicated.



**Supplementary Figure 6. Close-up views of the active site of AusE in complex with αKG.** Structure shows the octahedral coordination of  $Mn^{2+}$  by the HxDx<sub>n</sub>H motif, the C-2 oxo group and C-1 carboxylate of  $\alpha$ KG, and a water molecule (W). The *m*Fo-*D*Fc omit electron density map of Mn, w1, and αKG are represented as a black mesh, contoured at +3.5 σ. Interatomic distances are average values of Chain A and Chain C.



**Supplementary Figure 7. Close-up views of the active site of apo PrhA and its complex structure with αKG.** (a) The active site of the apo-state PrhA. A water molecule (W) was located in the center of HxDx<sub>n</sub>H motif. The *m*Fo-*D*Fc omit electron density map of w1 are represented as a black mesh, contoured at +6.0 σ. **(b)** The active site of PrhA-Fe(II)/αKG. The *m*Fo-*D*Fc omit electron density map of Fe, w1, and αKG are represented as a black mesh, contoured at +4.0 σ.



**Supplementary Figure 8. Interaction of the active site residues with α-ketoglutarate (a) or preaustinoid A1 (5) (b) in PrhA-Fe/αKG/5 structure.**



Supplementary Figure 9. Omit map of ligands in chain B. Close-up views of the ligand of PrhA in complex with (**a**) **5**, PrhA-V150L/A232S in complex with (**b**) **5**, (**c**) **6**, (**d**) **7**, and (**e**) **3**, PrhA-V150L/A232S/M241V in complex with (**f**) **3**. The *m*Fo-*D*Fc omit electron density maps of ligands are represented as a gray mesh, contoured at (**a**) +2.0 σ, (**b**) +2.0 σ, (**c**) +3.0 σ, (**d**) +3.0 σ, (**e**) +2.5 σ, and (**f**) +3.0 σ respectively.



**Supplementary Figure 10. C-terminal hairpin of chain A and the flexible loop form a lid in the active site of PrhA. (a)** Active site of chain B contains ligand **5** (orange stick), which interacts with Loop A (yellow) of chain B and Hairpin B (cyan) of chain A (closed form). The side chains of Ser66 and Asp276' form hydrogen bond network with **5**. **(b)** In the case of chain A, the Loop A has moved away from the active site and the C-terminal hairpin of chain B is not observed in the absence of ligand **5** (open form). **(c)** Superimposition of the active sites of chain B **(a**, closed form**)** and chain A **(b**, open form**)**. Loop A has is 5.4 Å closer to the ligand **5** in chain B compared to chain A.



Supplementary Figure 11. The D-ring of 5 directly interacts with  $\alpha$ KG and Hairpin B in **PrhA-Fe/αKG/5 structure. (a)** The substrate **5** shown as sphere model or **(b)** stick model. The substrate **5** is sandwiched between the  $\alpha$ KG and Hairpin B with Asp276'. This interaction is likely to be important for substrate binding and release as  $\alpha$ KG is consumed in each catalytic cycle.



**Supplementary Figure 12.** *In vitro* **enzyme reaction of PrhA-V150L/A232S/M241V.** HPLC chromatograms of the assays performed with (**iii**) mixture of **13** and **14**, (**v**) **14**, and (**vii**) **15**. (**ii**) Mixture of **13** and **14**, (**iv**) **14**, or (**vi**) **15** incubated in pH7.5 PIPES buffer for 12 hr in the absence of PrhA-V150L/A232S/M241V were used as negative controls. (**i**) Isolated **13** spontaneously converts into **14** in the reaction buffer in the absence of enzyme. Chromatograms were monitored at 223 nm.



**Supplementary Figure 13.** *In vitro* **enzyme reaction of AusE, PrhA, and PrhA mutants with berkeleyone A (3). (a)** HPLC chromatograms of the productions of reactions of PrhA, PrhA-V150L/A232S, PrhA-V150L/A232S/M241V, and AusE. All of the reactions were performed for 1 hr. Chromatograms were monitored at 223 nm. AusE and PrhA mutants catalyze C-5 hydroxylation of **3** to form **8**, as well as desaturation and spirocycle formation to form **9** and **10** from **4**. This shunt activity is lacking in the wild type PrhA.



**Supplementary Figure 14.** Close-up views of the active site of PrhA(V150L/A232S)-Fe/αKG/**3.** Substrate **3** is colored as pink.



**Supplementary Figure 15. Multiple sequence alignment of AusE, PrhA and their homologues.** Primary sequence alignment of AusE and PrhA, AusE', AndA, AndF, AsqJ, and FtmOx1 with the highest sequence similarity found by Blast search. The secondary structures of AusE and PrhA are delineated as follows: α-helices (cylinders), β-strands (arrows). The HxDxnH motif highlighted in pink is strictly conserved for

Fe(II) binding. The three active site residues important for controlling the  $\alpha$ KG oxygenase function (150, 232, and 241) are highlighted in yellow. Residues important for binding of the substrate highlighted in blue differ significantly among these homologues. Loop and hairpin regions constituting the substrate binding pocket are framed in blue and red dashed boxes, respectively. Accession numbers: AusE from *Aspergillus nidulans*  FGSC A4 (Q5AR34.1), PrhA from *Penicillium brasilianum* (BAV69302.1), AusE' from *Penicillium brasilianum* MG11 (CEJ61311.1), AndA from *A. stellatus* (BAP81855.1), AndF from *A. stellatus* (BAP81860.1), Trt7 from *A. terreus* NIH2624 (Q0C8A0.1), AsqJ from *A. nidulans* FGSC A4 (Q5AR53.1), FtmOx1 from *A. fumigatus* Af293 (Q4WAW9.1), and EasH from *Claviceps purpurea* 20.1 (G8GV69.1).



**Supplementary Figure 16. Phylogenetic tree of AusE, PrhA and their homologues fungal non-heme iron oxygenases.** Neighbor-joining method (MEGA 7) was used to generate this phylogenetic tree with a bootstrap test of 1,000 replicates. Bootstrap values given in percentages are shown at the nodes. AusE, AusE', and PrhA were surrounded by blue squares. These three enzymes are closely related. Accession numbers of AusE, PrhA, AusE', AndA, AndF, Trt7, AsqJ, FtmOx1, and EasH are the same as those used in Supplementary Figure 15.



**Supplementary Figure 17. M241V mutation in PrhA opens space for C-13 oxidation.** (**a**) The **7** was manually docked into the active site of the PrhA-V150L/A232S/M241V triple mutant using the coordinates from the complex structure of **7** and the PrhA-V150L/A232S double mutant. Compared to (**b**) the complex structure of **7** and the PrhA-V150L/A232S double mutant, M241V mutation provides additional space around C-13 to allow further oxidation at this position. The surface of Met241 is highlighted in red with **7** and the relevant residues shown as stick models. The distance between the indicated atoms are provided in Å.



**Supplementary Figure 18. Predicted stereochemistry of C-1 based on molecular modeling.** The C-1 chiral center in **14** is predicted to have *S* configuration based on the molecular models of **7**, **13** and **14** generated and energy minimized using ChemBio3D Ultra (14.0 MM2).

## **Supplementary Tables**

 $\overline{a}$ 

Supplementary Table 1. Data collection and refinement statistics for the x-ray structure of AusE in the absence of substrate.



\*Values in parentheses are for highest-resolution shell.

※Number of residues in favored region / allowed region / outlier region.

**Supplementary Table 2.** Data collection and refinement statistics for the x-ray structure of PrhA in the absence of substrate.



\*Values in parentheses are for highest-resolution shell.

※Number of residues in favored region / allowed region / outlier region.



**Supplementary Table 3.** Data collection and refinement statistics for the x-ray structure of wt and V150L/A232S PrhA solved in the presence of substrates.

\*Values in parentheses are for highest-resolution shell.

※Number of residues in favored region / allowed region / outlier region.

**Supplementary Table 4.** Data collection and refinement statistics for the x-ray structure of V150L/A232S and V150L/A232S/M241V PrhA solved in the presence of substrates.



\*Values in parentheses are for highest-resolution shell.

※Number of residues in favored region / allowed region / outlier region.

**Supplementary Table 5.** Distance table.





# nd: no density was observed for the side chain.

**Supplementary Table 6.** Primers used in this study.



## **Supplementary Note 1.**

#### **HRMS analysis of compound 13**

HRMS analysis revealed the molecular formula of compound 13 to be  $C_{26}H_{32}O_8$ , indicating the presence of additional oxygen atom compared to 7. HRMS  $(m/z)$ :  $[M+H]+$  calcd. for  $C_{26}H_{33}O_8$ , 473.5354; found, 473.5415.

## **Structural elucidation of compound 14**

HRMS analysis revealed the molecular formula of compound  $14$  to be  $C_{26}H_{32}O_8$  and its NMR data were similar to those of **7**, including spiro-lactone ring system. However, signals corresponding to allylic methyl group (C-13) and conjugated olefin moiety A-ring (C-1 and C-2) observed in 8 were absent in the NMR spectra of **14**. Instead, NMR data indicated the presence of one oxymethylene (C-11,  $\delta_H$  4.24,  $\delta_C$  68.9 ppm), oxymethine (C-1, δ<sub>H</sub> 3.65 ppm, δ<sub>C</sub> 84.5 ppm) and aliphatic methylene group (C-2, δ<sub>H</sub> 2.87 and 2.71 ppm, δ<sub>C</sub> 33.8 ppm), suggesting that allylic methyl group of **7** was oxidated. The planer structure was constructed based on the 2D NMR spectra including COSY, HSQC and HMBC. The presence of ether ring (E-ring) in **14** was confirmed based on the HMBC correlations of H-13/C-1 and downfield-shifted  $\delta_c$  value at C-1 position (84.5) ppm).

Considering **14** was directly converted from **7**, stereochemistries of **14** should be identical to those of **7** except for the newly generated chiral center at C-1 position. Although NOESY analysis did not conclude the stereochemistry at C-1 position, molecular modeling (Chem3D Ultra 14.0, MM2) of **7** and putative precursor **13** predicted whether the primary alcohol in **13** to attack from either side of C-1 position (Supplementary Figure 18), and the configuration of C-1 position expect to be *S* based on these observations.

Compound **14**: <sup>1</sup>H NMR (900 MHz, CDCl3):*δ* 5.54 (d, 1H, *J* = 1.0 Hz, H-1'), 5.04 (d, 1H, *J* = 1.0 Hz, H-1'), 4.24 (s, 2H, H-13), 3.80 (s, 3H, H-1''), 3.65 (t, 1H, *J* = 3.5 Hz, H-1), 2.87 (dd, 1H, *J* = 3.5, 17.5 Hz, H-2), 2.84 (ddd, 1H, *J* = 2.5, 4.5, 14.0 Hz, H-7), 2.71 (dd, 1H, *J* = 3.5, 17.5 Hz, H-2), 2.63 (d, 1H, *J* = 14.0 Hz, H-11), 2.27 (d, 1H, *J* = 14.0 Hz, H-11), 1.94 (ddd, 1H, *J* = 2.5, 4.5, 14.5 Hz, H-6), 1.73 (ddd, 1H, *J* = 4.5, 14.0, 14.0 Hz, H-7), 1.56 (s, 3H, H-12), 1.54 (s, 3H, H-9'), 1.45 (s, 3H, H-14), 1.31 (s, 3H, H-10'), 1.30 (s, 3H, H-15), 0.99 (ddd, 1H, *J* = 4.5, 14.0, 14.0 Hz, H-6). <sup>13</sup>C NMR (225 MHz, CDCl3): *δ* 206.2 (C-4'), 203.5 (C-6'), 170.1 (C-3), 169.3 (C-8'), 145.0 (C-2'), 138.9 (C-10), 130.6 (C-9), 114.2 (C-1'), 84.5 (C-1), 84.2 (C-4), 78.6 (C-5'), 72.2 (C-7'), 68.9 (C-13), 52.6 (C-1''), 51.4 (C-3'), 46.6 (C-5), 43.4 (C-8), 41.9 (C-11), 33.8 (C-2), 30.5 (C-7), 29.4 (C-15), 27.6 (C-14), 27.0 (C-6), 26.3 (C-12), 21.5 (C-9'), 15.5 (C-10'). HRMS (*m/z*): [M+H]<sup>+</sup> calcd. for  $C_{26}H_{33}O_8$ , 473.5354; found, 473.5415.

#### **Structural elucidation of compound 15**

HRMS analysis revealed the molecular formula of compound 15 to be  $C_{26}H_{32}O_9$ , indicating the presence of additional oxygen atom compared to 14. <sup>1</sup>H and <sup>13</sup>C NMR were nearly identical to those of 14, but 1D NMR spectra lacked the signal for C-1 oxymethine moiety observed in **14**. On the other hand, <sup>13</sup>C NMR spectrum showed new quaternary carbon signal at 104.1 ppm, suggesting that C-1 position of **14** was oxygenated and converted to hemiacetal group. It was supported by the HMBC correlations of H-2/C-1 and H-13/C-1, the down-field shifts of chemical shifts of C-2 (**15**: 40.7 ppm, **14**: 33.8 ppm) and C-5 (**15**: 51.5 ppm, **14**: 46.6 ppm) position. Because **15** was directly converted from **14** by enzymatic reaction, these compounds should share the same stereochemistries and the configuration of C-1 position was thought to be *S*.

Compound **15** <sup>1</sup>H NMR (900 MHz, CDCl3):*δ* 5.53 (s,1H, H-1'), 5.03 (s, 1H, H-1'), 4.37 (d, 1H, *J* = 13.0 Hz, H-13), 4.25 (dd, 1H, *J* = 2.5, 13.0 Hz H-13), 3.80 (s, 3H, H-1''), 2.89 (d, 1H, *J* = 17.0 Hz, H-2), 2.84 (m, 1H, H-7), 2.82 (d, 1H, *J* = 17.0Hz, H-2), 2.64 (d, 1H, *J* = 13.0, H-11), 2.22 (d, 1H, *J* = 13.0, H-11), 1.67 (m, 1H, H-7), 1.66 (m, 1H, H-6), 1.61 (m, 1H, H-6), 1.55 (s, 3H, H-12), 1.53 (s, 3H, H-9'), 1.50 (s, 3H, H-14), 1.35 (s, 3H, H-10'), 1.30 (s, 3H, H-15), 0.99 (ddd, 1H, *J* = 4.5, 14.0, 14.0, H-6). <sup>13</sup>C NMR (225 MHz, CDCl3): *δ* 206.6 (C-4'), 202.6 (C-6'), 169.5 (C-3), 169.4 (C-8'), 145.6 (C-2'), 137.2 (C-10), 131.2 (C-9), 113.7 (C-1'), 104.1 (C-1), 84.3 (C-4), 79.2 (C-5'), 72.1 (C-7'), 68.8 (C-13), 52.6 (C-1''), 51.5 (C-5), 51.4 (C-3'), 43.4 (C-8), 42.2 (C-11), 40.7 (C-2), 29.9 (C-7), 29.9 (C-15), 27.8 (C-14), 26.2 (C-12), 22.1 (C-6), 21.7 (C-9'), 14.6 (C-10'). HRMS (*m/z*): [M+H]<sup>+</sup> calcd. for C<sub>26</sub>H<sub>33</sub>O<sub>9</sub>, 489.5348; found, 489.5405.

#### **Structural elucidation of compound 16**

HRMS analysis revealed the molecular formula of compound  $16$  to be  $C_{26}H_{30}O_9$ . <sup>1</sup>H NMR spectrum showed very similar patterns to those of 7, including the signals corresponding to  $C-1/C-2$  double bond ( $\delta_H$ ) 6.57 ppm (H-1) and 5.93 ppm (H-2)). On the other hand, <sup>1</sup>H NMR data indicated that vinyl methyl group of C-13 position was absent in **16** as in the case of **15** and **14**. Because of low quantity of **16** and several signal broadening in NMR data, we could not assigned carbon resonances corresponding to C-1, C-10 and C-13, although the large parts of planer structure was fully elucidated by analyzing 1D ( $^1$ H and  $^13$ C) and 2D (COSY, HSQC and HMBC) NMR data set. However, these spectroscopic data and the fact **16** was enzymatically converted from **13** or **7** (not from **15** and **14**) strongly indicated that **16** is the analogue of **7** whose C-13 methyl group was oxidized to carboxylic acid. It was further confirmed that **16** was converted to corresponding methyl ester by treating with TMS-diazomethane.

Compound **16** <sup>1</sup>H NMR (900 MHz, CD<sub>3</sub>OD): $\delta$  6.57 (brs, 1H, H-1), 5,93 (d, 1H,  $J = 9.5$ ), 5.45 (s,1H, H-1'), 4.94 (s, 1H, H-1'), 3.71 (s, 3H, H-1''), 2.75 (brd, 1H, *J* = 15.0 Hz, H-11), 2.67 (m, 1H, H-7), 2.53 (brd, 1H, *J*  $= 15.0$ Hz, H-11), 2.05 (m, 1H, H-7), 1.79 (m, 1H, H-6), 1.62 (s, 3H, H-14), 1.61 (m, 1H, H-6), 1.52 (s, 3H, H-12), 1.43 (s, 3H, H-9'), 1.40 (s, 3H, H-15), 1.38 (s, 3H, H-10'). <sup>13</sup>C NMR (225 MHz, CD3OD): *δ* 207.1 (C-4'), 205.2 (C-6'), 169.5 (C-8'), 143.1 (C-2'), 132.7\* (C-9), 118.9\* (C-2), 112.8 (C-1'), 86.1 (C-4), 76.4 (C-5'), 71.6 (C-7'), 51.3 (C-3'), 50.9 (C-1''), 45.2\* (C-5), 44.8 (C-8), 42.5 (C-11), 25.5\* (C-6), 24.5 (C-7), 23.9 (C-15), 22.4 (C-14), 22.0 (C-12), 20.4 (C-9'), 17.6 (C-10') (\*The chemical shifts were determined based on HMBC and HSQC correlations. \*\* carbon resonances corresponding to C-1, C-10 and C-13 were not assigned due to low quantity of 21 and signal broadening.). HRMS  $(m/z)$ :  $[M+H]^+$  calcd. for C<sub>26</sub>H<sub>31</sub>O<sub>9</sub>, 487.5189 ; found, 487.5245.

### **Methyl esterification of 16**

 A small part of **16** (ca. 30 µg) was dissolved in 200 µl of methanol and excess amount of TMS-diazomethane (10 µl of 0.6 M hexane solution) was added and the mixture was stirred for 1 h at room temperacture. The reaction was quenched by removing TMS-diazomethane by evaporation and the resulting residue was re-dissolved in 50 µl of methanol for LC-HRMS analysis.









NMR spectra of compound 14. (a) <sup>1</sup>H NMR (900 MHz), (b) <sup>13</sup>C NMR (225 MHz), (c) COSY (900 MHz), (d) HSQC (900 MHz), (e) HMBC (900 MHz), (f) NOESY (900 MHz). All data were measured in CDCl<sub>3.</sub>









NMR spectra of compound **15**. (a) <sup>1</sup>H NMR (900 MHz), (b) <sup>13</sup>C NMR (225 MHz), (c) COSY (900 MHz), (d) HSQC (900 MHz), (e) HMBC (900 MHz), (f) NOESY (900 MHz). All data were measured in CDCl3.



200

 $\frac{1}{50}$ 

[ppm]





NMR spectra of compound **16**. (a) <sup>1</sup>H NMR (900 MHz), (b) <sup>13</sup>C NMR (225 MHz), (c) COSY (900 MHz), (d) HSQC (900 MHz), (e) HMBC (900 MHz). All data were measured in CD<sub>3</sub>OD.